Search

The U.S. biosciences industry directly employs 1.74 million people and indirectly supports $2.0 trillion in economic output and roughly 8 million jobs nationwide, according to "Investment, Innovation and Job Creation in a Growing U.S. Biosciences Industry," a new report by TEConomy Partners on behalf of the trade association BIO. The report, released at BIO’s annual conference last week, finds that biosciences venture capital investment is reaching new highs, while overall innovation ecosystem strength and patent activity is bolstered by increasing NIH budgets and growth in academic R&D. The report’s authors also take an in-depth look at the industry, its components, its contributions to the national economy, and the state and metropolitan areas where it is most concentrated.

Two new hubs have been announced in the Manufacturing USA network, one focusing on sustainable manufacturing innovation and the other on tissue biofabrication, bringing the total network of institutes to 13 since its inception four years ago.

Because a research base that generates new knowledge is a key pillar of a technology-based economy, an important strategy in technology-based economic development is the expansion of research capacity. While states may go about addressing this in a variety of ways (e.g., R&D tax-credits, university-industry partnerships, recruiting eminent scholars), Florida drew national attention when it took a different approach last decade, allocating more than $450 million to attract nine research institutes through its Innovation Incentive Program (IIP). Recently, one of those attracted institutes, the San Diego-based Sanford-Burnham Prebys Medical Discovery Institute – which received approximately $367 million in state and local incentives to open an Orlando location – announced that it was having discussions with the University of Florida to exit the state and turn the Florida operations over to the university.

The Indiana Biosciences Research Institute (IBRI), first unveiled in May 2013, is a statewide public-private partnership advanced by BioCrossroads that considers itself the first industry-led collaborative life sciences research institute in the country. Late last month, the institute announced two new grants totaling $100 million that would support scientific innovation addressing metabolic disease and poor nutrition. 

Biotech is in the midst of an investment boom, at least in Silicon Valley. In the first quarter of this year, biotech firms in the region raised $574 million, the third highest quarter on record, according to data from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA) and reporting by the San Jose Mercury News. This peak represents a 103 percent increase over the same quarter the previous year. Nationwide, the sector is poised to attract a record-setting $7 billion this year, according to Bloomberg Business. However, Silicon Valley's biotech boom is less apparent in other parts of the country.

Over the past decade stem cell research has been touted as a game-changer in the life sciences and a potential fount of new biomedical innovations. As a result, several states have launched targeted programs to support stem cell research, despite the controversy that tends to surround the field. New research suggests that these programs have been effective at increasing the output of researchers in their respective states. State investments in California and Connecticut have helped researchers outperform their colleagues around the country, according to a recent paper published in Cell Stem Cell. Programs in New York and Maryland did not have quite the same impact, but helped research output in those states keep pace with other states.

Minnesota’s economic future may well be rooted in its historic leadership in agricultural production, according to a new report prepared by Battelle, Agbioscience as a Development Driver: Minnesota Agbioscience Strategy. The report includes an assessment of Minnesota’s key capacities and opportunities in agricultural research and a suggested strategy for the state with a specific focus on growing the state’s agricultural bioscience (agbioscience) research infastructure. After interviewing more than 100 researchers and research administrators, the authors identified four agbioscience research platform areas to target:

The National Institutes of Health (NIH) is accepting applications for the Research Evaluation and Commercialization Hub (REACH) program to support proof-of-concept centers (Hubs) that facilitate and accelerate the translation of biomedical innovations into commercial products that improve patient care and enhance health. NIH intends to award approximately $9 million to institutions of higher education to establish three new REACH Hubs. In addition to helping identify innovations appropriate for commercialization, REACH Hubs must provide entrepreneurial educational opportunities to academic investigators about the design and conduct of product definition studies and the commercialization processes required for transitioning a technology out of academic labs to the private sector via a startup venture or a licensing agreement. Applications are due June 26. Read the federal funding announcement…

Massachusetts’ continuing success in the biopharmaceutical sector depends on finding new ways to fund startup and early stage research activities, according to a new strategic plan released by the Massachusetts Biotechnology Council (MassBio). The report cites recent data showing that life sciences venture capital has fallen by 50 percent over the past five years and many investors have turned to later stage investments. In place of this model of startup funding, the group recommends engagement with a number of alternative funding channels, including angel groups, foundations, wealthy individuals and crowdfunding services. The report also includes a number of other recommendations to improve the environment for new and growing life sciences firms.